Injectable PLA-based in situ forming implants for controlled release of Ivermectin a BCS Class II drug: Solvent selection based on physico-chemical characterization

Drug Development and Industrial Pharmacy

Volumn 39, Issue 1, 2013, Pages 146-155

  Camargo, J A ^a   Sapin, A ^a   Nouvel, C ^b   Daloz, D ^b   Leonard, M ^b   Bonneaux, F ^a   Six, J L ^b   Maincent, P ^a  

^a UNIVERSITÉ DE LORRAINE   (France)

^b UNIVERSITÉ DE LORRAINE   (France)

Author keywords

Biocompatible; In situ forming implants; Ivermectin; PLA; Sustained release

Indexed keywords

1 METHYL 2 PYRROLIDINONE; 2 PYRROLIDINONE; BENZYL BENZOATE; IVERMECTIN; POLYLACTIDE; TRIACETIN;

ARTICLE; BIOCOMPATIBILITY; BIODEGRADABILITY; CONTROLLED RELEASE FORMULATION; DRUG IMPLANT; FLOW KINETICS; GEL PERMEATION CHROMATOGRAPHY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; IN SITU FORMING IMPLANT; MISCIBILITY; PHYSICAL CHEMISTRY; POROSITY; SCANNING ELECTRON MICROSCOPY; VISCOSITY;

ANTIPARASITIC AGENTS; BIOCOMPATIBLE MATERIALS; DELAYED-ACTION PREPARATIONS; DRUG COMPOUNDING; DRUG DELIVERY SYSTEMS; INJECTIONS; IVERMECTIN; PARTICLE SIZE; POLYESTERS; SOLUBILITY; SOLVENTS;

EID: 84871228596     PISSN: 03639045     EISSN: 15205762     Source Type: Journal    
DOI: 10.3109/03639045.2012.660952     Document Type: Article

References (36)

1. Dunn RL, English JP, Cowsar DR & Vanderbilt DP. 1990. Biodegradable in-Situ forming implants and methods of producing the same, Us Patent 4,938,763. July 3.
2. Hatefi A, Amsden B. 2002. Biodegradable injectable in situ forming drug delivery systems. J Control Release, 80:9-28. (Pubitemid 34273745)
3. Jain RA. 2000. The manufacturing techniques of various drug loaded biodegradable poly(lactide-Co-Glycolide) (PLGA) devices. Biomaterials, 21:2475-2490.
4. Shah NH, Railkar AS, Chen FC, Tarantino R, Kumar S, Murjani, M, Palmer, D, Infeld, MH, Malick, AW. 1993. A biodegradable injectable implant for delivering micro and macromolecules using poly (lactic-Co-Glycolic) acid (PLGA) copolymers. J Control Release 27:139-147. (Pubitemid 23328982)
5. Deadman CM, Kellaway IW, Yasin M, Dickinson PA, Murdan S. 2007. An investigation into the influence of drug lipophilicity on the in vivo absorption profiles from subcutaneous microspheres and in situ forming depots. J Control Release, 122:79-85. (Pubitemid 47284556)
6. Ravivarapu HB, Moyer KL, Dunn RL. (2000). Parameters affecting the efficacy of a sustained release polymeric implant of leuprolide. Int J Pharm, 194:181-191. (Pubitemid 30110680)
7. Wang L, Kleiner L, Venkatraman S. (2003). Structure formation in injectable poly(lactide-Co-Glycolide) depots. J Control Release, 90:345-354. (Pubitemid 36859965)
8. Packhaeuser CB, Schnieders J, Oster CG, Kissel T. (2004). In situ forming parenteral drug delivery systems: An overview. Eur J Pharm Biopharm, 58:445-455. (Pubitemid 39037247)
9. Chen G, Junnarkar, G. 2008 Alzamer Depot bioerodible polymer technology. In: Rathbone MJ, Hadgraft, J, Roberts MS, Lane EM, editors. Modified-release drug delivery technology. Vol. 2. New York, USA: Informa Helath care, p.215-225, 703., Vol.2.
10. Omura S. (2008). Ivermectin: 25 years and still going strong. Int J Antimicrob Agents, 31:91-98.
11. Takano R, Sugano K, Higashida A, Hayashi Y, Machida M, Aso Y et al. 2006. Oral absorption of poorly water-Soluble drugs: Computer simulation of fraction absorbed in humans from a miniscale dissolution test. Pharm Res, 23:1144-1156. (Pubitemid 43946137)
12. Gokbulut C, Karademir U, Boyacioglu M, McKellar QA. 2006. Comparative plasma dispositions of ivermectin and doramectin following subcutaneous and oral administration in dogs. Vet Parasitol, 135:347-354. (Pubitemid 43117016)
13. González Canga A, Sahagún Prieto AM, José Diez Liébana M, Martínez NF, Vega MS, Vieitez JJ. 2009. The pharmacokinetics and metabolism of ivermectin in domestic animal species. Vet J, 179:25-37.
14. Anderson JM, Shive MS. 1997 Biodegradation and biocompatibility of PLA and PLGA microspheres. Adv Drug Deliver Rev, 8:5-24. (Pubitemid 27497671)
15. Legrand P, Lesieur S, Bochot A, Gref R, Raatjes W, Barratt G et al. 2007. Influence of polymer behaviour in organic solution on the production of polylactide nanoparticles by nanoprecipitation. Int J Pharm, 344:33-43. (Pubitemid 47464822)
16. Matschke C, Isele U, van Hoogevest P, Fahr A. 2002. Sustainedrelease injectables formed in situ and their potential use for veterinary products. J Control Release, 85:1-15. (Pubitemid 35449450)
17. Liu J, Chang, Z, Sun, X, Shen S, Lei C & Liu H. 2006 Impurity effects on the crystallization of avermectin B1a. J Cryst Growth, 291:448-454. (Pubitemid 43810123)
18. Huggins, ML. 1942. The viscosity of diluted solutions of longchain molecules Iv. Dependence of concentration. J Am Chem Soc, 64, 2716-2718.
19. Brodbeck KJ, DesNoyer JR, McHugh AJ. 1999. Phase inversion dynamics of PLGA solutions related to drug delivery. Part II. The role of solution thermodynamics and bath-Side mass transfer. J Control Release, 62:333-344. (Pubitemid 29476581)
20. Graham PD, Brodbeck KJ, McHugh AJ. 1999. Phase inversion dynamics of PLGA solutions related to drug delivery. J Control Release, 58:233-245. (Pubitemid 29112894)
21. Kranz H Bodmeier R. 2008. Structure formation and characterization of injectable drug loaded biodegradable devices: In situ implants versus in situ microparticles. Eur J Pharm Sci, 34:164-172.
22. Shively ML, Coonts BA, Renner WD, Southard JL, Bennett, AT. 1995. Physico-Chemical characterization of a polymeric injectable implant delivery system. J Control Release, 33, 237-243.
23. Dong WY, Körber M, López Esguerra V, Bodmeier R. 2006. Stability of poly(D,L-lactide-Co-Glycolide) and leuprolide acetate in in-Situ forming drug delivery systems. J Control Release, 115:158-167. (Pubitemid 44537494)
24. Kranz H, Brazeau GA, Napaporn J, Martin RL, Millard W, Bodmeier R. 2001. Myotoxicity studies of injectable biodegradable in-Situ forming drug delivery systems. Int J Pharm, 212:11-18. (Pubitemid 32121946)
25. Royals MA, Fujita SM, Yewey GL, Rodriguez J, Schultheiss PC, Dunn RL. 1999. Biocompatibility of a biodegradable in situ forming implant system in rhesus monkeys. J Biomed Mater Res, 45:231-239. (Pubitemid 29165939)
26. Löffler D, Ternes TA. 2003. Determination of acidic pharmaceuticals, antibiotics and ivermectin in river sediment using liquid chromatography-Tandem mass spectrometry. J Chromatogr A, 1021:133-144. (Pubitemid 37357019)
27. Lambert WJ, Peck, KD. 1995 Development of an in situ forming biodegradable poly-lactide-Co-Glycolide system for the controlled release of proteins. J. Control. Release, 33, 189-195.
28. Hansen CM. 1967 The three dimensional solubility parameterkey to paint component affinities: Ii and Iii. J Paint Technol, 39, 505-514.
29. Hansen CM. 2007. Hansen solubility parameters: A user's handbook. New York: CRC Press, 1-24.
30. Alfrey T. 1947 The influence of solvent composition on the specific viscosities of polymer solutions. J Colloid Interf Sci, 2: 99-114.
31. Rungseevijitprapa W, Bodmeier R. 2009. Injectability of biodegradable in situ forming microparticle systems (ISM). Eur J Pharm Sci, 36:524-531.
32. Wang L, Venkatraman S, Kleiner L. 2004. Drug release from injectable depots: Two different in vitro mechanisms. J Control Release, 99:207-216. (Pubitemid 39222107)
33. Kempe S, Metz H, Mäder K. 2008. Do in situ forming PLG/NMP implants behave similar in vitro and in vivö A non-Invasive and quantitative EPR investigation on the mechanisms of the implant formation process. J Control Release, 130:220-225.
34. Körber M, Bodmeier R. 2008. Development of an in situ forming PLGA drug delivery system I. Characterization of a non-Aqueous protein precipitation. Eur J Pharm Sci, 35:283-292.
35. Siepmann J, Göpferich A. 2001. Mathematical modeling of bioerodible, polymeric drug delivery systems. Adv Drug Deliv Rev, 48:229-247. (Pubitemid 32434405)
36. Hon HC, Singh, RP, Kudchadker, AP. 1976 Vapor pressureboiling point measurements of five organic substances by twin ebulliometry. JChem Eng. Data, 21, 430-431.